OpenLB
Open Library of Bioscience
Advanced Search
World journal of gastroenterology
Aug 07, 2021;27 (29): 4831-4845.

Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease.

Tiffany Khoo, Danielle Lam, John K Olynyk
Author Information
  1. Tiffany Khoo: Department of Gastroenterology and Hepatology, Fiona Stanley Hospital, Murdoch 6150, Australia.
  2. Danielle Lam: Department of Gastroenterology and Hepatology, Fiona Stanley Hospital, Murdoch 6150, Australia.
  3. John K Olynyk: Department of Gastroenterology and Hepatology, Fiona Stanley Hospital, Murdoch 6150, Australia.
PMID: 34447229 DOI: 10.3748/wjg.v27.i29.4831

Abstract

Chronic infections with the hepatitis B and C viruses have significant worldwide health and economic impacts. Previous treatments for hepatitis C such as interferon and ribavirin therapy were ineffective and poorly tolerated by patients. The introduction of directly acting curative antiviral therapy for hepatitis C and the wider use of nucleos(t)ide analogues for suppression of chronic Hepatitis B infection have resulted in many positive developments. Decreasing the prevalence of hepatitis B and C have concurrently reduced transmission rates and hence, the number of new infections. Antiviral treatments have decreased the rates of liver decompensation and as a result, lowered hospitalisation and mortality rates for both chronic hepatitis B and C infection. The quality of life of chronically infected patients has also been improved significantly by modern treatment. Antiviral therapy has stopped the progression of liver disease to cirrhosis in certain patient cohorts and prevented ongoing hepatocellular damage in patients with existing cirrhosis. Longer term benefits of antiviral therapy include a reduced risk of developing hepatocellular carcinoma and decreased number of patients requiring liver transplantation. This review article assesses the literature and summarises the impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes from liver disease.

Keywords

Clinical outcomes Directly acting antiviral therapy Hepatitis B Hepatitis C Liver disease Nucleotide analogues

References

  1. Hepatology. 2013 Nov;58(5):1537-47 [PMID: 23389810]
  2. Arthritis Rheum. 1990 Aug;33(8):1065-7 [PMID: 2390119]
  3. Gastroenterology. 2019 Jan;156(2):446-460.e2 [PMID: 30367836]
  4. Clin Gastroenterol Hepatol. 2015 Jun;13(6):1181-8.e1 [PMID: 25460550]
  5. Medicine (Baltimore). 2005 Sep;84(5):313-322 [PMID: 16148731]
  6. J Hepatol. 2005 Nov;43(5):764-70 [PMID: 16087273]
  7. J Clin Gastroenterol. 2002 May-Jun;34(5):569-72 [PMID: 11960072]
  8. J Hepatol. 2016 Oct;65(4):741-747 [PMID: 27388925]
  9. Liver Int. 2018 Dec;38(12):2170-2177 [PMID: 29750389]
  10. Gastroenterology. 2014 Jul;147(1):152-61 [PMID: 24583062]
  11. Gastroenterology. 2016 Jan;150(1):145-155.e4; quiz e15-6 [PMID: 26386298]
  12. J Med Virol. 2017 Dec;89(12):2181-2187 [PMID: 28688190]
  13. J Gastroenterol. 2009;44(9):991-9 [PMID: 19554391]
  14. Zhonghua Yi Xue Za Zhi. 2007 Jul 10;87(26):1832-5 [PMID: 17922993]
  15. World J Gastroenterol. 2008 Mar 21;14(11):1652-6 [PMID: 18350595]
  16. Clin Liver Dis. 2004 May;8(2):403-18 [PMID: 15481347]
  17. World J Hepatol. 2018 Sep 27;10(9):612-621 [PMID: 30310539]
  18. J Gastroenterol Hepatol. 2012 Oct;27(10):1589-95 [PMID: 22554121]
  19. Eur J Gastroenterol Hepatol. 2021 May 1;33(5):727-730 [PMID: 32558698]
  20. J Hepatol. 2016 Oct;65(4):692-699 [PMID: 27242316]
  21. Hepatology. 2013 Jul;58(1):98-107 [PMID: 23213040]
  22. Gastroenterology. 2018 Nov;155(5):1436-1450.e6 [PMID: 30031138]
  23. J Hepatol. 2017 Sep 5;: [PMID: 28887168]
  24. Hepatology. 2011 Mar;53(3):774-80 [PMID: 21294143]
  25. Clin Liver Dis. 2016 Nov;20(4):681-692 [PMID: 27742007]
  26. Am J Physiol Gastrointest Liver Physiol. 2016 Feb 1;310(3):G143-54 [PMID: 26608186]
  27. Gastroenterology. 2017 Oct;153(4):996-1005.e1 [PMID: 28642197]
  28. Hepatology. 2017 Nov;66(5):1454-1463 [PMID: 28628942]
  29. Gastroenterol Clin North Am. 2015 Dec;44(4):807-24 [PMID: 26600221]
  30. Hepatology. 2011 Jan;53(1):62-72 [PMID: 21254162]
  31. J Hepatol. 2016 Sep;65(3):524-31 [PMID: 27212241]
  32. J Viral Hepat. 2004 Mar;11(2):97-107 [PMID: 14996343]
  33. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 [PMID: 21296855]
  34. Gastroenterology. 2016 Jun;150(7):1599-1608 [PMID: 26924097]
  35. J Med Virol. 2013 Nov;85(11):1900-6 [PMID: 23926082]
  36. Aliment Pharmacol Ther. 2009 Sep 1;30(5):469-76 [PMID: 19508612]
  37. J Gastroenterol Hepatol. 2019 Dec;34(12):2187-2195 [PMID: 31062880]
  38. Hepatol Commun. 2017 May 23;1(5):439-452 [PMID: 29404471]
  39. Aliment Pharmacol Ther. 2016 Oct;44(8):846-55 [PMID: 27549411]
  40. J Hepatol. 2015 Apr;62(4):956-67 [PMID: 25595883]
  41. Eur J Gastroenterol Hepatol. 2019 Jan;31(1):16-23 [PMID: 30024489]
  42. J Gastrointestin Liver Dis. 2018 Sep;27(3):281-289 [PMID: 30240472]
  43. Gut. 2014 Oct;63(10):1648-57 [PMID: 24225939]
  44. Hepatology. 2017 Nov;66(5):1444-1453 [PMID: 28622419]
  45. Expert Rev Gastroenterol Hepatol. 2017 Dec;11(12):1095-1104 [PMID: 28752768]
  46. Hepatol Res. 2019 May;49(5):570-578 [PMID: 30623521]
  47. Clin Exp Rheumatol. 2011 Jan-Feb;29(1 Suppl 64):S110-6 [PMID: 21586205]
  48. Hepatology. 2010 May;51(5):1531-7 [PMID: 20087968]
  49. Adv Ther. 2020 Mar;37(3):1156-1172 [PMID: 32009232]
  50. Hepatology. 2015 Mar;61(3):790-801 [PMID: 25203718]
  51. J Hepatol. 2013 Mar;58(3):427-33 [PMID: 23123221]
  52. Hepatology. 2015 Jun;61(6):1809-20 [PMID: 25627342]
  53. PLoS One. 2016 Sep 28;11(9):e0163644 [PMID: 27680885]
  54. Dig Dis Sci. 2007 Oct;52(10):2531-9 [PMID: 17406828]
  55. J Med Virol. 2018 Feb;90(2):320-327 [PMID: 28960353]
  56. Public Health Rep. 2019 Nov/Dec;134(6):685-694 [PMID: 31577517]
  57. Clin Gastroenterol Hepatol. 2021 Sep;19(9):1950-1958.e7 [PMID: 32889148]
  58. J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:144-52 [PMID: 21199526]
  59. Aliment Pharmacol Ther. 2018 May;47(9):1278-1287 [PMID: 29516535]
  60. Liver Int. 2010 Aug;30(7):1033-42 [PMID: 20492502]
  61. Gastroenterol Hepatol (N Y). 2018 Jan;14(1):33-40 [PMID: 29491759]
  62. JGH Open. 2020 Mar 20;4(4):713-721 [PMID: 32782961]
  63. N Engl J Med. 1993 Dec 16;329(25):1842-7 [PMID: 8247035]
  64. J Viral Hepat. 2015 Feb;22(2):120-7 [PMID: 25040685]
  65. Am J Transplant. 2013 Feb;13(2):353-62 [PMID: 23137006]
  66. PLoS One. 2020 Jan 15;15(1):e0227532 [PMID: 31940324]
  67. J Hepatol. 2010 Feb;52(2):176-82 [PMID: 20006394]
  68. Value Health. 2018 Oct;21(10):1218-1225 [PMID: 30314623]
  69. Hepatol Res. 2018 Feb;48(3):E203-E212 [PMID: 28834042]
  70. Nat Rev Cancer. 2013 Feb;13(2):123-35 [PMID: 23344543]
  71. Dig Dis Sci. 2009 Jun;54(6):1337-46 [PMID: 19242792]
  72. Scand J Gastroenterol. 2018 Jun - Jul;53(7):857-863 [PMID: 29779403]
  73. Libyan J Med. 2018 Dec;13(1):1435124 [PMID: 29451090]
  74. J Hepatol. 2012 Aug;57(2):442-50 [PMID: 22504333]
  75. Gut. 2011 Aug;60(8):1109-16 [PMID: 21270118]
  76. Aliment Pharmacol Ther. 2018 Feb;47(4):516-525 [PMID: 29205405]
  77. J Viral Hepat. 2019 Feb;26(2):231-235 [PMID: 30339294]
  78. J Intern Med. 2019 Sep;286(3):290-298 [PMID: 31124596]
  79. J Hepatol. 2017 Aug;67(2):370-398 [PMID: 28427875]
  80. Hepatol Int. 2013 Jun;7(2):460-7 [PMID: 26201778]
  81. Hepatology. 2011 Jul;54(1):91-100 [PMID: 21503940]
  82. J Hepatol. 2015 May;62(5):1092-9 [PMID: 25445399]
  83. World J Gastroenterol. 2020 Nov 21;26(43):6770-6781 [PMID: 33268960]
  84. Aliment Pharmacol Ther. 2018 Apr;47(7):1012-1022 [PMID: 29424449]
  85. Liver Int. 2018 Aug;38(8):1402-1410 [PMID: 29288595]
  86. Aliment Pharmacol Ther. 2017 Jan;45(1):139-149 [PMID: 27910154]
  87. Ann Gastroenterol. 2015 Jan-Mar;28(1):109-117 [PMID: 25608681]
  88. Gastroenterology. 2014 Jul;147(1):143-151.e5 [PMID: 24704525]
  89. Gastroenterology. 2017 Jan;152(1):142-156.e2 [PMID: 27641509]

MeSH Term

Antiviral Agents
Carcinoma, Hepatocellular
Hepatitis B, Chronic
Hepatitis C, Chronic
Humans
Liver Cirrhosis
Liver Neoplasms
Quality of Life

Chemicals

Antiviral Agents
Journal Article Review
Article has an altmetric score of 7

Word Cloud

Created with Highcharts 10.0.0ChepatitisBtherapyantiviralliverpatientschronicdiseaseHepatitisratesmodernoutcomesinfectionstreatmentsactinganaloguesinfectionreducednumberAntiviraldecreasedcirrhosishepatocellularclinicalChronicvirusessignificantworldwidehealtheconomicimpactsPreviousinterferonribavirinineffectivepoorlytoleratedintroductiondirectlycurativewiderusenucleostidesuppressionresultedmanypositivedevelopmentsDecreasingprevalenceconcurrentlytransmissionhencenewdecompensationresultloweredhospitalisationmortalityqualitylifechronicallyinfectedalsoimprovedsignificantlytreatmentstoppedprogressioncertainpatientcohortspreventedongoingdamageexistingLongertermbenefitsincluderiskdevelopingcarcinomarequiringtransplantationreviewarticleassessesliteraturesummarisesimpactImpactClinicalDirectlyLiverNucleotide

Similar Articles

Cited By